(Q39974732)

16 September 2017

title

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model (English)

1 reference

16 September 2017

1 reference

Guru Sonpavde

1

1 reference

16 September 2017

Weiguo Jian

2

1 reference

16 September 2017

Hao Liu

3

1 reference

16 September 2017

Meng-Fen Wu

4

1 reference

16 September 2017

Steven S Shen

5

1 reference

16 September 2017

Seth P Lerner

6

1 reference

16 September 2017

publication date

4 June 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

27

1 reference

16 September 2017

issue

4

1 reference

16 September 2017

page(s)

391-399

1 reference

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

A Phase II study of oxaliplatin in urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Angiogenesis in bladder cancer--prognostic marker and target for future therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.03.017

10.1016/J.UROLONC.2008.03.017

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference